UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Date of Report (Date of earliest event reported): July 8, 2004
Biogen Idec Inc.
| Delaware | 0-19311 | 33-0112644 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
14 Cambridge Center, Cambridge, Massachusetts 02142
(Address of principal executive offices) (zip code)
Registrant’s telephone number, including area code: (617) 679-2000
Not Applicable
(Former name or former address, if changed since last report)
| Item 5. Other Events. | ||||||||
| SIGNATURES | ||||||||
Item 5. Other Events.
Michael Gilman, the registrant’s Senior Vice President, Research, entered into a Rule 10b5-1 sales plan on July 8, 2004. Sales under the plan are scheduled to take place between September 9, 2004 and September 9, 2005. All of the shares to be sold under the plan are the subject of stock options. The maximum number of shares which can be sold under the plan is 99,238.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Biogen Idec Inc. (Registrant) |
||
| Date: July 23, 2004 | /s/ Anne Marie Cook | |
| Anne Marie Cook Vice President, Chief Corporate Counsel |
3